Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Aug 27

PMID 34441758

Citations 8

Authors

Iosif Papafragkos

Efrosyni Markaki

Christina Kalpadakis

Panayotis Verginis

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs) are immature myeloid precursors which emerged as a potent regulator of the immune system, exerting suppressive properties in diverse disease settings. In regards to cancer, MDSCs have an established role in solid tumors; however, their contribution to immune regulation during hematologic malignancies and particularly in lymphomas remains ill-defined. Herein focused on lymphoma, we discuss the literature on MDSC cells in all histologic types, and we also refer to lessons learned by animal models of lymphoma. Furthermore, we elaborate on future directions and unmet needs and challenges in the MDSC field related to lymphoma malignancies which may shed light on the complex nature of the immune system in malignancies.

Citing Articles

Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma.

Efstratiou P, Damianaki A, Kavidopoulou A, Ioannidou P, Markaki E, Skianis I Front Med (Lausanne). 2025; 11:1515097.

PMID: 39944818 PMC: 11814433. DOI: 10.3389/fmed.2024.1515097.

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis.

Boumpas A, Papaioannou A, Bousounis P, Grigoriou M, Bergo V, Papafragkos I Front Immunol. 2024; 15:1386838.

PMID: 39464894 PMC: 11502414. DOI: 10.3389/fimmu.2024.1386838.

Skin repair and immunoregulatory effects of myeloid suppressor cells from human cord blood in atopic dermatitis.

Kim C, Hong S, Kim S, Yu J, Jung S, Bang C Front Immunol. 2024; 14:1263646.

PMID: 38264643 PMC: 10803405. DOI: 10.3389/fimmu.2023.1263646.

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.

Wang S, Zhao X, Wu S, Cui D, Xu Z Biomark Res. 2023; 11(1):34.

PMID: 36978204 PMC: 10049909. DOI: 10.1186/s40364-023-00475-8.

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers.

Fan R, De Beule N, Maes A, de Bruyne E, Menu E, Vanderkerken K Front Immunol. 2022; 13:1016059.

PMID: 36304465 PMC: 9592826. DOI: 10.3389/fimmu.2022.1016059.

References

Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge J, Abe J . Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111(12):5457-66. DOI: 10.1182/blood-2008-01-136895. View

Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G . S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res. 2011; 9(2):133-48. PMC: 3078037. DOI: 10.1158/1541-7786.MCR-10-0394. View

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S . Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998; 92(11):4150-66. View

Geskin L, Akilov O, Kwon S, Schowalter M, Watkins S, Whiteside T . Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother. 2017; 67(3):423-434. PMC: 8274400. DOI: 10.1007/s00262-017-2090-z. View

Wood K, Bushell A, Hester J . Regulatory immune cells in transplantation. Nat Rev Immunol. 2012; 12(6):417-30. DOI: 10.1038/nri3227. View

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Chaitchik S . Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999; 59(18):4681-7. View

Wu C, Wu X, Zhang X, Chai Y, Guo Q, Li L . Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med. 2015; 8(9):15173-81. PMC: 4658890. View

Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed M, Andueza M . Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin Cancer Res. 2016; 22(15):3924-36. DOI: 10.1158/1078-0432.CCR-15-2463. View

Hatziioannou A, Alissafi T, Verginis P . Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. J Leukoc Biol. 2017; 102(2):407-421. DOI: 10.1189/jlb.5VMR1116-493R. View

10.

Bennett J, Rao V, Mitchell M . Systemic bacillus Calmette-Guérin (BCG) activates natural suppressor cells. Proc Natl Acad Sci U S A. 1978; 75(10):5142-4. PMC: 336280. DOI: 10.1073/pnas.75.10.5142. View

11.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

12.

Sinha P, Clements V, Fulton A, Ostrand-Rosenberg S . Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007; 67(9):4507-13. DOI: 10.1158/0008-5472.CAN-06-4174. View

13.

Bunt S, Yang L, Sinha P, Clements V, Leips J, Ostrand-Rosenberg S . Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007; 67(20):10019-26. PMC: 4402704. DOI: 10.1158/0008-5472.CAN-07-2354. View

14.

Kim H, Park S, Seo S, Jung I, Yoon H, Gabrilovich D . The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018; 199(2):243-246. PMC: 6835091. DOI: 10.1164/rccm.201808-1502LE. View

15.

Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G . Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016; 7(19):27676-88. PMC: 5053680. DOI: 10.18632/oncotarget.8507. View

16.

Abedi-Valugerdi M, Wolfsberger J, Raghuram Pillai P, Zheng W, Sadeghi B, Zhao Y . Suppressive effects of low-dose 5-fluorouracil, busulfan or treosulfan on the expansion of circulatory neutrophils and myeloid derived immunosuppressor cells in tumor-bearing mice. Int Immunopharmacol. 2016; 40:41-49. DOI: 10.1016/j.intimp.2016.08.023. View

17.

Si Y, Merz S, Jansen P, Wang B, Bruderek K, Altenhoff P . Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue. Sci Immunol. 2019; 4(40). DOI: 10.1126/sciimmunol.aaw9159. View

18.

Alissafi T, Hatzioannou A, Mintzas K, Barouni R, Banos A, Sormendi S . Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018; 128(9):3840-3852. PMC: 6118632. DOI: 10.1172/JCI120888. View

19.

Sinha P, Okoro C, Foell D, Freeze H, Ostrand-Rosenberg S, Srikrishna G . Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008; 181(7):4666-75. PMC: 2810501. DOI: 10.4049/jimmunol.181.7.4666. View

20.

Kusmartsev S, Li Y, Chen S . Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol. 2000; 165(2):779-85. DOI: 10.4049/jimmunol.165.2.779. View